Technology Bundle ID

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Dan Li (NCI, CCR, LMB)
Mitchell Ho (NCI, CCR, LMB)
Nan Li (NCI, CCR, LMB)
Development Status
Pre-clinical (in vivo)

Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors.
Researchers in the National Cancer Institute (NCI) Laboratory of Molecular Biology (LMB) have created a new CAR format that is available for licensing and further co-development. This new format uses a specific promoter and signal peptide in a specific order allowing for increased efficiency of CAR T therapy. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. 
Additionally, the inventors are exploring the use of this new CAR T format in conjunction with other antibodies against multiple other cancer antigens, including mesothelin and glypican 2 (GPC2). 

Commercial Applications
  • Treating cancer patients eligible for ACT
  • Treating patients with diseases associated with expression of GPC3, GPC2, and other tumor antigens (e.g. mesothelin)  
Competitive Advantages
  • The novel technology (new CAR format) can increase therapeutic effectiveness of CAR T therapies for patients with solid tumor cancers (i.e., hepatocellular carcinoma or pancreatic cancer) where no long term or effective therapy currently exists
  • The novel technology (new CAR format) when used for immunotherapy in preclinical in vivo studies is already known to have a greater decrease in tumor size compared to those mice treated with other CAR formats

Request More Info

Licensing Contact: